Scientists at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology have developed a new method for producing human induced pluripotent stem cells from which the lentiviral reprogramming factors have been excised.

A Whitehead researcher said this week that the cells, derived from patients with sporadic Parkinson's disease, remained pluripotent and revealed a gene-expression profile that more closely resembled human embryonic stem cells than human iPS cells still carrying the reprogramming factors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.